Therapeutic drug monitoring in the treatment of tuberculosis: A retrospective analysis

International Journal of Tuberculosis and Lung Disease

Volumn 17, Issue 2, 2013, Pages

  Van Tongeren, L ^a   Nolan, S ^a   Cook, V J ^a,b   FitzGerald, J M ^a   Johnston, James C ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

Author keywords

Monitoring; Treatment; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG MONITORING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; TUBERCULOSIS;

EID: 84872339084     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.12.0279     Document Type: Article

References (30)

1. Peloquin C A. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002; 62: 2169-2183. (Pubitemid 35252827)
2. Peloquin C A. Use of therapeutic drug monitoring in tuberculosis patients. Chest 2004; 126: 1722-1724.
3. Um S-W, Lee S W, Know S Y, et al. Low serum concentrations of anti-tuberculosis drugs and determinants of their serum levels. Int J Tuberc Lung Dis 2007; 11: 972-978. (Pubitemid 47425023)
4. Van Crevel R, Alisjahbana B, de Lange W C M, et al. Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia. Int J Tuberc Lung Dis 2002; 6: 497-502. (Pubitemid 34601866)
5. Li J, Burzynski N, Lee Y, et al. Use of therapeutic drug monitoring for multidrug-resistant tuberculosis patients. Chest 2004; 126: 1770-1776. (Pubitemid 39643978)
6. Peloquin C A, MacPhee A A, Berning S E. Malabsorption of antimicrobial medications. N Engl J Med 1993; 329: 1122-1123.
7. Berning S E, Huitt G A, Iseman M D, Peloquin C A. Malabsorption of anti-tuberculosis medications by a patient with AIDS. N Engl J Med 1992; 327: 1817-1818.
8. Gurumurthy P, Ramachandran G, Kumar A K H, et al. Decreased bioavailability of rifampin and other anti-tuberculosis drugs in patients with advanced human immunodeficiency. A ntimicrob Agents Chemother 2004; 48: 4473-4475.
9. Peloquin C A, Nitta A T, Burman W J, et al. Low antit uberculosis drug concentrations in patients with AIDS. Ann Pharmacother 1996; 30: 919-923.
10. Sahai J, Gallicano K, Swick L, et al. Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Ann Intern Med 1997; 127: 289-293. (Pubitemid 27352050)
11. Gurumurthy P, Ramachandran G, Kumar A K H, et al. Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis. Clin Infect Dis 2004; 38: 280-283. (Pubitemid 38113038)
12. Tappero J W, Bradford W Z, Agerton T B, et al. Serum concentrations of anti-mycobacterial drugs in patients with tuberculosis in Botswana. Clin Infect Dis 2005; 41: 461-469. (Pubitemid 41099637)
13. Narita M, Hisada M, Thimmapa B, et al. Tuberculosis recurrence: multivariate analysis of serum levels of tuberculosis drugs, human immunodeficiency virus status, and other risk factors. Clin Infect Disease 2001; 32: 515-517. (Pubitemid 32173643)
14. Peloquin C A, Benator D, Hayden K. Low rifapentine, rifampin, and isoniazid plasma levels are not predicted by clinical and demographic factors [Abstract]. In: Proceedings and Abstracts of the 97th International Conference of the American Lung A ssociation/American Thoracic Society, San Francisco, CA, USA; May 18-23, 2001: 498.
15. Am J Respir Crit Care Med 2001; 163: A-498.
16. Peloquin C A. Tuberculosis drug serum levels. Clin Infect Dis 2001; 33: 584-585.
17. McIlleron H, Wash P, Burger A, Norman J, Folb P I, Smith P. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother 2006; 50: 1170-1177.
18. Weiner M, Benator D, Burman W, et al., and the Tuberculosis Trials Consortium. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 2005; 40: 1481-1491. (Pubitemid 40628637)
19. Heysell S K, Moore J L, Keller S H, Houpt E R. Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA. Emerg Infect Dis 2010; 16: 1546-1553.
20. Mehta J B, Shantaveerapa H, Byrd J R P Jr, Morton S E, Fountain F, Roy T M. Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy. Chest 2001; 120: 1520-1524. (Pubitemid 33078467)
21. Weiner M, Burman W, Vernon A, et al., and the Tuberculosis Trials Consortium. Low isoniazid concentration associated with outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Respir Crit Care Med 2003; 167: 1341-1347. (Pubitemid 36609717)
22. Kimerling M, Phillips P, Patterson P, Hall M, Robinson A, Dunlap N. Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients. Chest 1998; 113: 1178-1183. (Pubitemid 28223801)
23. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Disease Society of America. Treatment of tuberculosis. MMWR Rec Rep 2003; 52: 1-77.
24. Babalik A, Babalik A, Mannix S, Francis D, Menzies D. Therapeutic drug monitoring in the treatment of active tuberculosis. Can Respir J 2011; 18: 225-229.
25. Ray J, Gardiner I, Marriott D. Managing anti-tuberculosis drug therapy by therapeutic drug monitoring of rifampicin and isoniazid. Int Med J 2003; 33: 229-234. (Pubitemid 36718380)
26. Gordon S, Horsburgh C Jr, Peloquin C, et al. Low serum levels of oral antimycobacterial agents in patients with disseminated Mycobacterium avium complex disease. J Infect Dis 1993; 168: 1559-1562. (Pubitemid 23344925)
27. Patel K, Belmonte R, Crowe H. Drug malabsorption and resistant tuberculosis in HIV-infected patients. N Engl J Med 1995; 332: 336-337.
28. Jenne J, Beggs W. Correlation of in vitro and in vivo kinetics with clinical use of isoniazid, ethambutol and rifampin. Am Rev Respir Dis 1973; 107: 1013-1021.
29. Acocella G, Pagani V, Marchetti M, Baroni G C, Nicolis F B. Kinetic studies on rifampicin. I. Serum concentration analysis in subjects treated with different oral doses over a period of two weeks. Chemotherapy 1971; 16: 356-370.
30. Mitchison D A. The action of anti-tuberculosis drugs in short-course chemotherapy. Tubercle 1985; 66: 219-225. (Pubitemid 16150082)